1. Hypoglycemia Is BAD

3. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Hypoglycemia The Scope of the Problem

5. Hypoglycemia Session at ADA 2018

6. The Many Faces of Hypoglycemia Impact on Patient Health and Well-Being

7. Impact of Hypoglycemia on the Brain Insights From Structural and Functional Neuroimaging

8. Brain Structural Changes Seen in People With T1D and IAH

9. Hypoglycemia Unawareness and the Brain

10. Impact of Hypoglycemia on Patient-Reported Outcomes and Quality of Life

11. Hypoglycemia and CV Mortality

12. The Link Between Hypoglycemia and Arrhythmias

13. Hypoglycemia Session at ADA 2018 (cont)

14. Hypoglycemia—Who Is at Risk and Who Is Most Likely to Be Harmed?

15. Leveraging Technology to Detect, Prevent, and Treat Hypoglycemia

16. Hypoglycemia Session at ADA 2018 (cont)

17. New Definition of Hypoglycemia—Why Does It Matter?

18. Glucose Values Are Actionable Data

19. Economic Impact of Severe Hypoglycemia

20. SWITCH 2 Trial Design

21. Key Results from SWITCH 2 16-Week Maintenance Period

22. New Data From ADA 2018—SWITCH 2 Hypoglycemia by Age Group, 16-Week Maintenance Period

23. DEVOTE CV Outcomes Trial With Degludec

24. Key Results From DEVOTE

25. New Data From ADA 2018—DEVOTE CV Safety and Risk for Severe Hypoglycemia in Older Adults

26. BRIGHT Trial Glargine U300 vs Degludec U100

27. Incidence of Hypoglycemia Similar Between Glargine U300 and Degludec U100

28. Interpreting the BRIGHT, DEVOTE, and SWITCH Trials

29. Closing Comments

30. Abbreviations

31. Abbreviations (cont)